122
Participants
Start Date
August 30, 2020
Primary Completion Date
November 16, 2022
Study Completion Date
November 16, 2022
Bryostatin 1
Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
Placebo
Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
Neurological Associates of Albany, P. C., Albany
Alzheimer's Research Center, Matthews
iResearch Atlanta, Decatur
Atlanta Center for Medical Research, Atlanta
iResearch Savannah, Savannah
Columbus Memory Center, Columbus
Progressive Medical Research, Port Orange
Anchor Neuroscience, Pensacola
ClinCloud, Maitland
Galiz Research, Hialeah
Miami Dade Medical Research Institute, Miami
Alzheimer's Research and Treatment Center, Wellington
JEM Research, Atlantis
Fort Wayne Neurological Center, Fort Wayne
Millenium Psychiatric Associates, St Louis
Pacific Research Network, San Diego
Axiom Research, Colton
Summitt Research Network (Oregon), Portland
Kingfisher Cooperative, Spokane
Lead Sponsor
National Institutes of Health (NIH)
NIH
National Institute on Aging (NIA)
NIH
Neurotrope Bioscience, Inc.
INDUSTRY